Welcome to LookChem.com Sign In|Join Free
  • or
methyl (2S)-2-hydroxy-3-{N-[4-(4-chlorophenoxy)phenyl],N-methanesulfonylamino}propionate is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

1008531-10-9

Post Buying Request

1008531-10-9 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

1008531-10-9 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 1008531-10-9 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,0,8,5,3 and 1 respectively; the second part has 2 digits, 1 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 1008531-10:
(9*1)+(8*0)+(7*0)+(6*8)+(5*5)+(4*3)+(3*1)+(2*1)+(1*0)=99
99 % 10 = 9
So 1008531-10-9 is a valid CAS Registry Number.

1008531-10-9Relevant academic research and scientific papers

Microwave assisted ring-opening of epoxides with N-biaryl sulfonamides in the synthesis of matrix metalloproteinase-9 inhibitors

Yang, Shyh-Ming,Murray, William V.

, p. 835 - 839 (2008)

A microwave accelerated epoxide ring-opening process with N-biaryl sulfonamides is described. Under this mild, highly efficient condition, an α-hydroxy-β-N-biaryl sulfonamide skeleton is rapidly assembled leading ultimately to a novel series of matrix met

β-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: Part 1. Design, synthesis, and lead identification

Yang, Shyh-Ming,Scannevin, Robert H.,Wang, Bingbing,Burke, Sharon L.,Wilson, Lawrence J.,Karnachi, Prabha,Rhodes, Kenneth J.,Lagu, Bharat,Murray, William V.

, p. 1135 - 1139 (2008/12/22)

A new series of β-N-biaryl ether sulfonamide hydroxamates as novel gelatinase inhibitors is described. These compounds exhibit good potency for MMP-2 and MMP-9 without inhibiting MMP-1. The structure-activity relationships (SAR) reveal the biaryl ether ty

MATRIX METALLOPROTEASE INHIBITORS

-

Page/Page column 49; 53; 82, (2010/11/30)

The present invention relates to compounds of Formula I, wherein R1, R2, R3, R4, R5, R6, and R7 are defined in the specification. In addition, the present invention relates to methods treating disorders related to matrix metalloproteases. More particularl

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 1008531-10-9